Ï T.J. åîïìïëïãåßôáé...

Boy ÃåéÜ óå üëïõò.
Ç äéêéÜ ìïõ éóôïñßá åßíáé ìéá åíôåëþò äéáöïñåôéêÞ éóôïñßá áðü ôéò õðüëïéðåò.
ºóùò ìÜëéóôá ðáñáîåíåõôåßôå ëßãï.

ÊÜðïéá óôéãìÞ óôç æùÞ ìïõ ãíùñßæïìáé ìå ôïí Ì., Ýíáí ðáíÝìïñöï ôñéáíôÜ÷ñïíï íÝï.
Óôçí áñ÷Þ âãáßíáìå áñêåôÜ óõ÷íÜ áëëÜ ðïôÝ äåí Þèåëå íá êÜíïõìå óåî, üóåò öïñÝò êáé áí ôïõ ôï ðñüôåéíá.
¼óï åãþ ôïí ðëçóßáæá åñùôéêÜ, ôüóï åêåßíïò ìå áðùèïýóå.

¿óðïõ ôåëéêÜ äéÜëåîå íá ìïõ ðåé üôé åßíáé ïñïèåôéêüò üôáí åßìáóôá ìÝóá óôï áõôïêßíçôï.
Äåí ôï ðåñßìåíá. ¸ðáèá ôÝôïéï óïê ðïõ êüíôåøá íá ôñáêÜñù.
Ðáñüëá áõôÜ ãéá ìÝíá Þôáí áñãÜ ãéáôß ôïí åß÷á åñùôåõôåß ôñåëëÜ.
Ôïõ ðñüôåéíá íá êÜíïõìå ó÷Ýóç ìå êÜèå áíáãêáßá ðñïöýëáîç.
¼ìùò ï Ì. ìïõ æÞôçóå íá ÷ùñßóïõìå ãéáôß ðñïöáíþò èá öïâÞèçêå ìÞðùò ìå êïëëÞóåé ÜèåëÜ ôïõ.
Äåí ðßóôåøá üôé èá ôïí Ý÷áíá. ¹ìïõí ôõöëùìÝíïò áðü Ýñùôá. ÔñåëëÜèçêá.
Åßðá: «ÈåÝ ìïõ, ôïí èÝëù ðßóù êÜôù áðü ïðïéïäÞðïôå ôßìçìá.»

¼óï êáé áí ðñïóðÜèçóá íá ôïí îáíáðëçóéÜóù, ôßðïôá. Ôñåéò ìÞíåò Ýêëáéãá. ¸ìåéíá ï ìéóüò áðü ôçí êáôÜèëéøç.
ÔåëéêÜ ìÝóá óôïí åñùôéêü ìïõ ðáñïîõóìü Ýêáíá ôï ôåëåßùò ôñåëëü. ¸êáíá áõôü ðïõ öáíôÜæåóôå. ¢ñ÷éóá íá øÜ÷íù ìÝóá áðü ôï ºíôåñíåô ïñïèåôéêÜ Üôïìá Ýôóé þóôå íá êïëëÞóù êé åãþ ôïí éü, þóôå íá öÝñù ðßóù ôïí Ì. ìïõ. Áí Þìïõíá êé åãþ ïñïèåôéêüò äåí èá öïâüôáí ðëÝïí ìÞðùò ìå êïëëÞóåé åêåßíïò ÜèåëÜ ôïõ.

Áöïý êáôÜöåñá íá êÜíù óåî ÷ùñßò ðñïöýëáîç ìå äéÜöïñá HIV+ Üôïìá åðß ó÷åäüí ìßá åâäïìÜäá, ðÞãá íá êÜíù ôï ôåóô ìåôÜ áðü 3 ìÞíåò óå êÜðïéï ìåãÜëï íïóïêïìåßï.
Äõóôõ÷þò üìùò ôï áðïôÝëåóìá âãÞêå áñíçôéêü. Äåí êáôÜöåñá íá êïëëÞóù ôïí éü!

ÂÜæù åê íÝïõ áããåëßá ìÝóù ºíôåñíåô ðïõ Ýëåãå üôé åßìáé ïñïèåôéêüò, ÷ùñßò óôçí ðñáãìáôéêüôçôá íá åßìáé.
ÊáôáöÝñíù íá âñþ Ýíá ïñïèåôéêü ðáéäß 24 ÷ñïíþí. Äåí ìïõ Üñåóå éäéáßôåñá áëëÜ Ýêáíá óáí ôñåëëüò ãéá íá êÜíïõìå óåî. Áõôüò äåí Ýðáéñíå öÜñìáêá áêüìá êáé åß÷å éúêü öïñôßï. ÊÜíáìå óåî åðß ôñåéò ìÝñåò ìáæß. ÊñÜôáãá ìÝóá ìïõ ôï óðÝñìá ôïõ ãéá íá óéãïõñåõôþ üôé èá êïëëÞóù.

Ëßãï áñãüôåñá üìùò ìáèáßíù áðü êÜðïéïí ãíùóôü ìïõ üôé åíôùìåôáîý ï Ì. Ýêáíå ó÷Ýóç ìå Üëëï ïñïèåôéêü Üôïìï!
ÊõñéïëåêôéêÜ åß÷á êáôáóôñáöåß. ÐåñíÜíå äýï ìÞíåò êé åãþ åßìá áêüìá ìå áõôüí ôïí 24÷ñïíï ïñïèåôéêü.

¸öôáóå ç ìÝñá íá êÜíù îáíÜ ôï ôåóô ãéá HIV. ÐÞãá êáé ôï Ýêáíá ëïéðüí. ÐÞñá ôçí áðÜíôçóç óôá ÷Ýñéá ìïõ.
¹ôáí èåôéêÞ!

Êáé ôþñá... ôé êÜíïõìå;

¸÷áóá ôïí Ì. ðïõ ëÜôñåõá. ¸÷ù ôïí Ã. ðïõ äåí ìïõ áñÝóåé êáé ìéá íÝá êáèçìåñéíÞ æùÞ ìå áíôéñåôñïúêÜ öÜñìáêá.

¸ôóé áðëü÷åñá Ýêáíá ôï ÷åéñüôåñï äþñï óôïí åáõôü ìïõ.

Åý÷ïìáé íá ìçí âñåèåß ðïôÝ êáíåßò óôç èÝóç ìïõ. Åý÷ïìáé íá åßìáé ï ôåëåõôáßïò ôñåëëÜ åñùôåõìÝíïò ðïõ Ýêáíå êÜôé ôÝôïéï ôüóï áíüçôï!




... 'Aëëåò éóôïñßåò ...

+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò